ArticleJournal of veterinary internal medicine
Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMild-moderate asthma is common in horses. Inhaled ciclesonide has been approved only for treatment of severe asthma in horses. HYPOTHESIS/
objectivesWe hypothesized that a 10-day treatment course of inhaled ciclesonide (Aservo EquiHaler) would improve clinical signs, endoscopic tracheal mucus scores, and bronchoalveolar lavage fluid (BALF) cytology in racehorses with moderate asthma. ANIMALS: Racehorses with moderate asthma housed at the Emerald Downs Racetrack in Auburn, WA.
methodsProspective, randomized, double-blinded, placebo-controlled clinical study. Horses received inhaled ciclesonide (n = 12) or placebo (n = 9) for 10 days. Clinical signs were assessed at different times using the Tesarowski and HOARSI scores and cough during exercise. Endoscopy scoring, BALF cytology, and BALF cell selected gene expression (RT-qPCR) were assessed on Days 0 and 10. Linear and ordinal simple and mixed effects models were used to analyze the data using R statistical software. Significance was set at P < .05.
resultsOnly treated horses showed a decrease over time in HOARSI (P ≤ .001), cough (P = .001; -2.83 [-4.37, -1.29]), mast cell % (P = .03; -2.68 [-4.36, -1.0]) and relative expression of IL-6 (P = .002; 0.44 [0.04, -6.99]) and IL-13 (P = .03; 0.52 [0.04, -7.89]) in BAL cells. Treated horses had lower HOARSI (P = .002; -1 [1, 1]) and mast cell % (P = .02; -2.96 [-5.52, -0.39]) on Day 10. CONCLUSION AND CLINICAL IMPORTANCE: Treatment with inhaled ciclesonide improved clinical signs and decreased BALF mastocytic inflammation in racehorses with moderate asthma without change in the environment. Treatment effect on neutrophilic or eosinophilic asthma remains undetermined. The small number of horses was a study limitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.